- Home
- SANA vs ALLO Comparison
SANA vs ALLO Comparison
Compare SANA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | ALLO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.1M | 707.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SANA | ALLO |
|---|---|---|
| Price | $3.29 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $7.80 | ★ $8.35 |
| AVG Volume (30 Days) | 2.8M | ★ 8.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.24 | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.61 | $0.99 |
| 52 Week High | $6.55 | $4.46 |
Technical Indicators
Market Signals| Indicator | SANA | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 31.83 |
| Support Level | $3.03 | $1.56 |
| Resistance Level | $3.41 | $1.92 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 23.30 | 8.26 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).